Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma is a research paper published in Journal of Clinical Investigation (2020). On theSindex it has a DataRank of 0. It has been cited 71 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Research UK Program Grant
Grant: C34648/A18339
Cancer Research UK Program Grant
Grant: C34648/A14610
EPSRC Cancer Imaging Centre
Grant: C1060/A10334
ICR CRUK Imaging Centre
Grant: C1090/A16464
The Wellcome Trust
Grant: 091763Z/10/Z
NIH and NCI
Grant: 1R01CA215452-01
CRUK
Grant: C309/A11566,C24461/A23302
CHILDREN with CANCER UK
Grant: 2014/176,2014/174
NB UK
Grant: .
Christopher’s smiles
Grant: CSM001X
Cancer Research UK
Grant: 16464
Sparks Charity
Grant: 12RMH01
Cancer Research UK
Grant: 14610
Cancer Research UK
Grant: 27725
Cancer Research UK
Grant: C34648/A28278
Cancer Research UK
Grant: 23302
Cancer Research UK
Grant: 28278
Medical Research Council
Grant: MC_PC_18051
NCI NIH HHS
Grant: R01 CA215452
The Brain Tumour Charity
Grant: 6/88
Cancer Research UK
Grant: C24461/A23302
Cancer Research UK
Grant: 22897
Medical Research Council
Grant: MC_PC_16047
Children with Cancer UK
Grant: 14-176
Cancer Research UK
Grant: C309/A11566
National Institute for Health Research (NIHR)
Wellcome Trust
MeSH Terms
Keywords